GetTopicDetailResponse(id=4e4f6441984, topicName=沃森, introduction=沃森, content=null, image=null, comments=1, allHits=1588, url=https://h5.medsci.cn/topic?id=64419, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=17496, tagList=[TagDto(tagId=17496, tagName=沃森)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1192704, encodeId=e9471192e04f3, content=國內應該開放輝瑞的mRNA疫苗，國內的<a href='/topic/show?id=de9d66915e9' target=_blank style='color:#2F92EE;'>#滅活疫苗#</a>差距還是十分大的，就算是<a href='/topic/show?id=4e4f6441984' target=_blank style='color:#2F92EE;'>#沃森#</a>的mRNA疫苗，現(xiàn)在看來差距也很大，其副作用高到難以接受的地步！開放輝瑞<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>進入國內，也是正途呀, objectTitle=重磅！輝瑞新冠病毒口服藥物Paxlovid，國內獲附條件批準, objectType=article, longId=295532, objectId=6d76295532fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220127/c7777b79af69484fa3e753ef4ac78ba9.jpg, objectUrl=/article/show_article.do?id=6d76295532fc, replyNumber=0, likeNumber=195, createdTime=2022-02-12, rootId=0, userName=醫(yī)者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d76295532fc, moduleTitle=重磅！輝瑞新冠病毒口服藥物Paxlovid，國內獲附條件批準, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6d76295532fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
